Company to reimburse more than those whose tests were voided and corrected; Resolution ends all existing and potential claims against Theranos in the state.
CMS withdraws revocation of CLIA certificates and reduces civil monetary penalty; Theranos withdraws appeal, completing exit from the clinical lab business.
Theranos, Inc. announced that engineering and biomedical device design experts have joined the company’s newly created Technology Advisory Board (TAB).
Riley Bechtel Retires from Board; Company to Retire Board of Counselors Structure in Consolidation of Advisory Framework
Theranos Unveils Its Diagnostic-Testing Technologies at American Association for Clinical Chemistry Meeting
Theranos outlines research and development technologies to miniaturize analytical testing equipment.
Theranos also is creating a Compliance and Quality Committee, headed by newly appointed member of Board of Directors
Theranos responds to the CMS's recent notice of sanctions.